Lumara Health Inc.
http://www.lumarahealth.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lumara Health Inc.
Women’s Health Expert Panel Addresses Challenges, Opportunities In Post-Roe Era
After years of underfunding, stigmatization and lack of research, companies working on products and services that address women’s health care are gaining traction. But the sector also faces unique challenges, such as gaining approval for ads on major social media platforms.
Should Obese Patients Be Included In Every Drug Development Program?
FDA officials question whether modeling tools can predict which drugs have different disposition in obese populations. They say physiologically-based pharmacokinetic data cannot be used as a surrogate for actual clinical trial data at this time.
Organon CEO Uncertain Over Long-Term Future Of Biosimilars Business
Organon CEO Kevin Ali has acknowledged that the long-term future for the biosimilars business is unclear, despite the firm’s biosimilars segment currently acting as a solid growth driver for the company.
Organon Foresees US Adalimumab Discounts Hitting 80%-90%
Organon CEO Kevin Ali has suggested that discounts for US Humira biosimilars could “range anywhere between 80% and 90%” by 2025-2026, amid a slew of competition on adalimumab starting within weeks.
Company Information
- Other Names / Subsidiaries
-
- Ethex Corporation
- K-V Pharmaceutical Company (KV Pharmaceutical)
- Ther-Rx Corporation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice